Transforming the Medicine of Tomorrow -Today

About the Program in Personalized Medicine and Targeted Therapeutics (P2MT2)TM

The Program in Personalized Medicine & Targeted Therapeutics (P2MT2)TM was founded in 2001 as one of the first centers focused on pharmacogenomics and personalized medicine by Dr. Amalia Issa to advance the science and translation of personalized medicine through state-of-the-art research and education.

The key question that drives our research is: What is needed for personalized medicine to be well-integrated into clinical practice and effectively incorporated into health care delivery and health systems?

We are a multidisciplinary group of faculty, staff, students, fellows and collaborators who conduct research aimed at understanding how personalized medicine applications will be translated from bench to bedside to community and integrated effectively into clinical practice and health care delivery.




The mission of the Program in Personalized Medicine & Targeted Therapeutics is to develop the evidence base for, promote informed decision-making about, and accelerate knowledge translation of personalized medicine into meaningful health outcomes.

The Program accomplishes its mission through state-of-the-art research, training programs, consultation to government agencies on public policy initiatives, and national and international collaborations.


To be the leading source of evidence for policy-relevant research on genomic diagnostics and novel technological applications of personalized medicine.